

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013  
Year of Birth: 1954  
Age: 69 Year(s)  
Sex: Male  
Race: Other  
Has the subject fasted for at least 10 hours?:YES

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA  
Date of Collection: 08-Mar-2024  
Time of Collection: 10:48  
Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
Chemistry						12-Mar-2024

Sample Barcode: A014DG0EA  
Received: 12-Mar-2024

Hemoglobin A1c	7.5	H	[ ]Yes [ ]No	4.0 - 6.0	%
----------------	-----	---	--------------	-----------	---

Platelet Estimate performed via site prepared slide.  
WBC differential originated from an automated count.

Sample Barcode: A014KFIJL  
Received: 12-Mar-2024

Sodium	136			134 - 144	mEq/L
Potassium	4.3			3.5 - 5.1	mmol/L
Chloride	102			95 - 110	mmol/L
Bicarbonate	25			21 - 33	mmol/L
BUN	21			5 - 22	mg/dL
Creatinine	1.35			0.62 - 1.44	mg/dL
GFR (MDRD 6 Variable)	55	L	[ ]Yes [ ]No	> 60	mL/min/1.73m <sup>2</sup>
Glucose	187	NH, R	[ ]Yes [ ]No	60 - 115	mg/dL
Total Protein	7.5			6.0 - 8.0	g/dL
Albumin	4.0			3.5 - 5.5	g/dL
Calcium	9.8			8.5 - 10.5	mg/dL
Magnesium	1.7	L	[ ]Yes [ ]No	1.8 - 2.4	mg/dL
Phosphorus	3.7			2.5 - 4.8	mg/dL

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 1 of 13

## Laboratory Report

**MEDPACE**  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?:YES

Site: 0128  
Investigator: Dr. Anita Kohli

Subject have Gilbert's Syndrome?: NO

Historical ALT/AST available?: YES

Height (cm): 177

Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Chemistry (Continued)</b>						<b>12-Mar-2024</b>
Uric Acid	6.5			4.0 - 8.5	mg/dL	
Bilirubin (Total)	0.75			0.25 - 1.20	mg/dL	
Bilirubin (Direct)	0.16			0.00 - 0.20	mg/dL	
ALT/SGPT	24			6 - 41	U/L	
AST/SGOT	27			9 - 34	U/L	
Alkaline Phosphatase	42			37 - 116	U/L	
Gamma Glutamyl Transferase (GGT)	83	H	[ ]Yes [ ]No	11 - 52	U/L	
Amylase	50			22 - 123	U/L	
Lipase	54			11 - 82	U/L	
Creatine Kinase (CK)	80			25 - 210	U/L	
Lactate Dehydrogenase (LDH)	128			113 - 226	U/L	
MELD Score	11	R		(None)	(None)	
NAFLD Fibrosis score	2.039	R		(None)	(None)	
AST to Platelet Ratio Index (APRI)	0.9	R		(None)	(None)	
FIB-4	4.4	R		(None)	(None)	
Insulin	32.8	H	[ ]Yes [ ]No	2.6 - 24.9	μIU/mL	

--- NAFLD Fibrosis score Comment ---

NAFLD Score < -1.455 = Negative (F0-F2)

NAFLD Score -1.455-0.676 = Indeterminate

NAFLD Score >0.676 =

Positive (F3-F4)

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High

\$2: See Protocol Section 9.6.7.2

ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 2 of 13

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?: YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Lipids</b>						<b>12-Mar-2024</b>
Sample Barcode: A014KFIJM Received: 12-Mar-2024						
Total Cholesterol	Blinded			100 - 200	mg/dL	
Triglyceride	Blinded			50 - 150	mg/dL	
HDL - Cholesterol (ppt)	Blinded			35 - 60	mg/dL	
LDL - Cholesterol (ppt calc)	Blinded			50 - 130	mg/dL	
non-HDL Cholesterol (calc)	Blinded			80 - 160	mg/dL	
LDL-C (Direct)	Blinded			50 - 130	mg/dL	
VLDL Cholesterol	Blinded			(None)	mg/dL	
Apolipoprotein AI	Blinded			110 - 205	mg/dL	
Apolipoprotein B	Blinded			55 - 105	mg/dL	
Lipoprotein (a)	Blinded			<= 75	nmol/L	
Lipoprotein (a) mass conversion	Blinded			<2 - 30	mg/dL	
hs-C-Reactive Protein	0.8			0.0 - 3.0	mg/L	

--- Lipoprotein (a) mass conversion Comment ---

Lp(a) analysis performed using a molar method, a conversion factor of 2.5 was applied to approximate the Lp(a) result in mass units, mg/dL

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 3 of 13

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?:YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Hormones / Cardiac</b>						<b>12-Mar-2024</b>
Sample Barcode: A014DG0DL Received: 12-Mar-2024						
Thyroxine-Binding Globulin	Pending					
Sample Barcode: A014DG0DM Received: 12-Mar-2024						
Free T3	3.5			2.0 - 4.4	pg/mL	
Free T4	Blinded			0.70 - 1.60	ng/dL	
Thyroid Stimulating Hormone (TSH)	1.70			0.40 - 4.00	μIU/mL	
T3	1.5			0.8 - 2.0	ng/mL	
T4	Blinded			5.1 - 14.1	μg/dL	
Sex Hormone Binding Globulin	Blinded			10.00 - 80.00	nmol/L	
Follicle Stimulating Hormone (FSH)	13.2	H	[ ]Yes [ ]No	1.6 - 11.0	mIU/mL	
Luteinizing Hormone (LH)	17.0	H	[ ]Yes [ ]No	1.7 - 8.6	mIU/mL	
Estradiol	61	H	[ ]Yes [ ]No	<39	pg/mL	
Total Testosterone	Blinded			2.70 - 10.70	ng/mL	
Free Testosterone	Blinded			0.18 - 0.71	nmol/L	
Ferritin	89			30 - 400	ng/mL	
CK-MB Mass	3.9			<15.0	ng/mL	
Troponin I	< 0.3			< 0.3	ng/mL	

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 4 of 13

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013  
Year of Birth: 1954  
Age: 69 Year(s)  
Sex: Male  
Race: Other  
Has the subject fasted for at least 10 hours?: YES

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA  
Date of Collection: 08-Mar-2024  
Time of Collection: 10:48  
Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Hormones / Cardiac (Continued)</b>						<b>12-Mar-2024</b>
--- Estradiol Comment ---						
Female estradiol reference intervals:						
Follicular phase: <151 pg/mL (< 554.2 pmol/L)						
Ovulation phase: 78 - 452 pg/mL (286.3 – 1658.8 pmol/L)						
Luteal phase: 40 - 191 pg/mL (146.8 – 701.0 pmol/L)						
Postmenopause: < 20 pg/mL (< 73.4 pmol/L)						
Pregnancy (1st trimester): >195 pg/mL (> 715.7 pmol/L)						
<b>Sample Barcode: A014DG0CP</b>						
<b>Received: 12-Mar-2024</b>						
%Carbohydrate-deficient Transferrin	Pending					

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
§2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?:YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Metabolic</b>						<b>12-Mar-2024</b>
Sample Barcode: A014DG0DY Received: 12-Mar-2024						
Insulin	30.2	H	[ ]Yes [ ]No	2.6 - 24.9	μIU/mL	
Glucose	184	NH, R	[ ]Yes [ ]No	60 - 115	mg/dL	
Homeostatic model assessment of insulin resistance	13.72			(None)	(None)	
Sample Barcode: A014DG0E2 Received: 12-Mar-2024						
Fibrinogen	Pending					
Sample Barcode: A014DG0CR Received: 12-Mar-2024						
Free Fatty Acids	Pending					
Adipo-IR	Pending					

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 6 of 13

## Laboratory Report

**MEDPACE**  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?: YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>ELF Test</b>						
Sample Barcode: A014PFY88						
Received: 12-Mar-2024						
Tissue Inhibitor of Metalloproteinase 1	Pending					
Hyaluronic Acid	Pending					
Amino-terminal propeptide of type III procollagen	Pending					
Enhanced Liver Fibrosis Test (ELF)	Pending					

--- Enhanced Liver Fibrosis Test (ELF) Comment ---

ELF interpretation: Risk cut-offs for the likelihood of disease progression to cirrhosis and development liver-related clinical events:

Lower risk: < 9.80

Mid risk: ≥ 9.80 - < 11.30

High risk: ≥ 11.30

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 7 of 13

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?:YES

Site: 0128  
Investigator: Dr. Anita Kohli

Subject have Gilbert's Syndrome?: NO

Historical ALT/AST available?: YES

Height (cm): 177

Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Hematology</b>						<b>12-Mar-2024</b>
Sample Barcode: A014DG0EA Received: 12-Mar-2024						
White Blood Cells	2.9	L, R	[ ]Yes [ ]No	3.5 - 11.0	10 <sup>3</sup> /μL	
Red Blood Cells	3.70	L, R	[ ]Yes [ ]No	4.30 - 6.00	10 <sup>6</sup> /μL	
Hemoglobin	12.0	L, R	[ ]Yes [ ]No	13.6 - 18.0	g/dL	
Hematocrit	37	L, R	[ ]Yes [ ]No	40 - 52	%	
MCV	99.6	H, R	[ ]Yes [ ]No	82.0 - 98.0	fL	
MCH	33	R		27 - 34	pg	
MCHC	32.7	R		32.0 - 36.0	g/dL	
Platelet	87	L, R	[ ]Yes [ ]No	140 - 400	10 <sup>3</sup> /μL	
Neutrophil %	64.3	R		40.0 - 80.0	%	
Lymphocyte %	26.8	R		15.0 - 45.0	%	
Monocyte %	2.6	R		0.0 - 12.0	%	
Eosinophil %	5.8	\$2, R		0.0 - 10.0	%	
Basophil %	0.5	R		0.0 - 4.0	%	
Neutrophil (Absolute)	1.86			1.00 - 8.00	10 <sup>3</sup> /μL	
Lymphocyte (Absolute)	0.78	L	[ ]Yes [ ]No	1.00 - 5.00	10 <sup>3</sup> /μL	
Monocyte (Absolute)	0.1	R		0.0 - 1.0	10 <sup>3</sup> /μL	
Eosinophil (Absolute)	0.2	R		0.0 - 0.8	10 <sup>3</sup> /μL	
Basophil (Absolute)	0.0	R		0.0 - 0.3	10 <sup>3</sup> /μL	
WBC Estimate	Decreased	L	[ ]Yes [ ]No	Normal	(None)	

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 8 of 13



## Laboratory Report

**MEDPACE**  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Subject have Gilbert's Syndrome?: NO

Age: 69 Year(s)

Historical ALT/AST available?: YES

Sex: Male

Height (cm): 177

Race: Other

Weight (kg): 089.6

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has the subject fasted for at least 10 hours?: YES

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Hematology (Continued)</b>						<b>12-Mar-2024</b>
Platelet Estimate	Decreased	L	[ ]Yes [ ]No	Normal	(None)	
RBC Morphology	Normal			(None)	(None)	

Platelet Estimate performed via site prepared slide.

WBC differential originated from an automated count.

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 9 of 13

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Age: 69 Year(s)

Sex: Male

Race: Other

Has the subject fasted for at least 10 hours?:YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
Urinalysis						12-Mar-2024
Sample Barcode: A014DG0EH Received: 12-Mar-2024	Time of Collection:		10:55			
Glucose	Normal	ST		Normal	mg/dL	
Bilirubin	Negative	ST		Negative	mg/dL	
Ketone	Normal	ST		Normal	mg/dL	
Specific Gravity	1.009	ST		1.002 - 1.035	(None)	
Blood	Negative	ST		Negative	mg/dL	
pH	5.0	ST		5.0 - 8.0	(None)	
Protein	Negative	ST		Negative	mg/dL	
Urobilinogen	Normal	ST		Normal	mg/dL	
Nitrite	Negative	ST		Negative	(None)	
Leukocyte Esterase	Negative	ST		Negative	Leu/μL	

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 10 of 13

## Laboratory Report

**MEDPACE**  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Subject have Gilbert's Syndrome?: NO

Age: 69 Year(s)

Historical ALT/AST available?: YES

Sex: Male

Height (cm): 177

Race: Other

Weight (kg): 089.6

Has the subject fasted for at least 10 hours?: YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>Coagulation / PAI-1</b>						<b>12-Mar-2024</b>
Sample Barcode: A014KFIJK						
Received: 12-Mar-2024						
Prothrombin Time (PT)	14.2			11.9 - 14.6	Sec	
International Normalized Ratio (INR)	1.1			0.8 - 1.2	(None)	
Activated Partial Thromboplastin Time (APTT)	30.7			23.9 - 40.0	Sec	

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
§2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013  
Year of Birth: 1954  
Age: 69 Year(s)  
Sex: Male  
Race: Other  
Has the subject fasted for at least 10 hours?: YES

Site: 0128  
Investigator: Dr. Anita Kohli  
Subject have Gilbert's Syndrome?: NO  
Historical ALT/AST available?: YES  
Height (cm): 177  
Weight (kg): 089.6

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA  
Date of Collection: 08-Mar-2024  
Time of Collection: 10:48  
Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>ARUP Laboratories</b>						
Address: 500 Chipeta Way, Salt Lake City, Utah 84108, USA						
<b>Sample Barcode: A014DG0DP</b>						
<b>Received: 12-Mar-2024</b>						
Alkaline Phosphatase (ARUP)	Pending					
Alkaline Phosphatase Bone	Pending					
Alkaline Phosphatase Liver	Pending					
Alkaline Phosphatase Other	Pending					
<b>Sample Barcode: A014DG0DN</b>						
<b>Received: 12-Mar-2024</b>						
Triiodothyronine, Reverse	Pending					

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 12 of 13

## Laboratory Report

# MEDPACE

  
Medpace Reference Laboratories-US

Lab Director: Traci Turner, MD  
5365 Medpace Way, Cincinnati, OH 45227, USA  
Tel: 513.366.3270 or 800.749.1737. Fax: 513.366.3273  
www.medpacelab.com

Sponsor: Madrigal  
Pharmaceuticals, Inc  
Protocol: MGL-3196-19  
Subject ID: 0128-9013

Site: 0128  
Investigator: Dr. Anita Kohli

Address: The Institute for Liver Health dba Arizona  
Liver Health  
2201 W. Fairview St Suite 9  
Chandler AZ 85224 USA

Year of Birth: 1954

Subject have Gilbert's Syndrome?: NO

Age: 69 Year(s)

Historical ALT/AST available?: YES

Sex: Male

Height (cm): 177

Race: Other

Weight (kg): 089.6

Has the subject fasted for at least 10 hours?: YES

Date of Collection: 08-Mar-2024

Time of Collection: 10:48

Timepoint: Week 52

Has subject had 2 or more dialysis treatments in the prior week, or has the subject received 24 hours of CVVHD?: NO

Comments:

Test	Result	Flag	Clin. Significant?	Ref Range	Units	Run Date
<b>NMS Labs</b>						
Address: 200 Welsh Road, Horsham, PA 19044, USA						
<b>Sample Barcode: A014DG0EE</b>						
<b>Received: 12-Mar-2024</b>						
Phosphatidylethanol, Blood	Pending					

Flag Definitions: L: Reference Low NL: Notable Low CL: Critical Low R: Rechecked Value  
H: Reference High NH: Notable High CH: Critical High  
\$2: See Protocol Section 9.6.7.2  
ST: Sample assessed out of stability window, determined to be analytically valid by technologist,  
clinical validity to be determined by investigator.

Investigator's Comments:

Investigator's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Report Date & Time: 12-Mar-2024 10:55:07PM

Page 13 of 13